NOF to Exhibit and Present a poster at SITC 2025 (Nov 7-8)
NOF CORPORATION is pleased to announce its participation in the upcoming SITC 2025
A Strategic Collaboration to Accelerate LNP-based Drug Development
NOF Corporation joins the LNP Alliance, bringing advanced lipid expertise to accelerate lipid nanoparticle drug development.
NOF to Exhibits and Presents at PODD 2025 (Oct 27 – 28)
NOF CORPORATION is pleased to announce its participation in the upcoming Partnerships Opportunities in Drug Delivery (PODD) 2025, which will be held at Westin Copley Place, Boston, MA, USA on October 27 and 28.The company is a Technology Track sponsor of the event.
Polysorbate 80 (HX2)™ Is in Compliance With The Chinese Pharmacopoeia
Polysorbate 80 (HX2)™, NOF AMERICA’s ultrapure polysorbate 80, has achieved compliance with USP, EP, JP, and the Chinese Pharmacopoeia (ChP for injection), enabling pharmaceutical product development for the Chinese market.